Results 321 to 330 of about 225,419 (363)

Towards an expanded neurocognitive account of ketamine's rapid antidepressant effects. [PDF]

Int J Neuropsychopharmacol
Dai Y, Harrison BJ, Davey CG, Steward T.
europepmc   +1 more source

Efficacy of perioperative esketamine on postoperative depression: a systematic review and meta-analysis. [PDF]

Front Psychiatry
Li HY, Xu WJ, Wang YM, Xie S, Wang HL.
europepmc   +1 more source

Abdominal Pain and Dysuria Secondary to Chronic Recreational Ketamine Use: A Case Report on K-cramps. [PDF]

Cureus
Boccio E, Haidar J, Thiefault M, Lutwak N, Kohen B, Atia H.   +5 more
europepmc   +1 more source

Protocol of an open-label safety and feasibility pilot study of ketamine-assisted psychotherapy for methamphetamine use disorder (the KAPPA trial). [PDF]

BMJ Open
Fletcher K, Ezard N, Siefried KJ, MacDonald H, Acheson L, Bedi G, Guerin A, Knock E, Millard M, May R, Brett J, Doumany J, Morgan C, Clifford B.   +13 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression.

New England Journal of Medicine, 2023
BACKGROUND Electroconvulsive therapy (ECT) and subanesthetic intravenous ketamine are both currently used for treatment-resistant major depression, but the comparative effectiveness of the two treatments remains uncertain.
A. Anand, S. Mathew, G. Sanacora, J. Murrough, F. Goes, Murat Altinay, Amy Aloysi, A. Asghar-Ali, B. Barnett, Lee C Chang, K. Collins, S. Costi, Sidra Iqbal, M. Jha, K. Krishnan, D. Malone, Sina Nikayin, S. Nissen, R. Ostroff, I. Reti, S. Wilkinson, K. Wolski, Bo Hu   +22 more
semanticscholar   +1 more source

Long-term safety of ketamine and esketamine in treatment of depression

Expert Opinion on Drug Safety, 2022
Introduction Ketamine can produce rapid-acting antidepressant effects. Esketamine (Spravato), the S-enantiomer of racemic ketamine, was approved by the FDA for treatment-resistant depression in 2019.
Sina Nikayin, Eva L. Murphy, J. Krystal, S. Wilkinson   +3 more
semanticscholar   +1 more source

A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder.

American Journal of Psychiatry, 2021
OBJECTIVE Posttraumatic stress disorder (PTSD) is a chronic and disabling disorder, for which available pharmacotherapies have limited efficacy. The authors' previous proof-of-concept randomized controlled trial of single-dose intravenous ketamine ...
A. Feder, S. Costi, S. Rutter, A. Collins, Usha Govindarajulu, M. Jha, S. Horn, Marin M. Kautz, M. Corniquel, K. Collins, L. Bevilacqua, Andrew Glasgow, Jess Brallier, R. Pietrzak, J. Murrough, D. Charney   +15 more
semanticscholar   +1 more source

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.

Archives of General Psychiatry, 1994
BACKGROUND To characterize further behavioral, cognitive, neuroendocrine, and physiological effects of subanesthetic doses of ketamine hydrochloride in healthy human subjects.
J. Krystal, L. Karper, J. Seibyl, G. K. Freeman, R. Delaney, J. Bremner, G. Heninger, M. Bowers, D. Charney   +8 more
semanticscholar   +1 more source